Burning Rock Announces 2022 Annual General Meeting to be Held on September 8, 2022
August 03 2022 - 2:12AM
Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or
“Burning Rock”), a company focusing on the application of next
generation sequencing (NGS) technology in the field of precision
oncology, today announced that it will hold its annual general
meeting (“AGM”) on September 8, 2022 at 10:00 a.m. (local time) at
the Company’s Shanghai office at 5/F, Building 1, No. 138
Xinjunhuan Road, Minhang District, Shanghai.
The AGM will be held for the following proposals:
- To ratify the appointment of Ernst
& Young Hua Ming LLP as auditor of the Company for the fiscal
year ending December 31, 2022 and to authorize the directors of the
Company to determine the remuneration of the auditor;
- To re-elect Feng Deng, Leo Li and
Licen Lisa Xu as directors of the Company;
- To approve, confirm and ratify the
adoption of the 2022 Long-term Equity Incentive Plan and the grant
of options thereunder, the vesting of which is tied to the
Company’s future stock performances (and options granted to Mr.
Han, the Company’s founder, chairman and chief executive officer,
will only start to vest after the Company’s market capitalization
reaches US$4 billion). The 2022 Long-term Equity Incentive Plan and
the grant of options thereunder are intended to replace the
Company’s 2021 Long-term Equity Incentive Plan and the share
incentive awards granted thereunder, which were approved by the
Company’s board of directors on November 3, 2021 and shareholders
on December 28, 2021; and
- To authorize each of the directors
of the Company to take any and all action that might be necessary
to effect the foregoing resolutions as such director, in his or her
absolute discretion, thinks fit.
The board of directors of the Company has fixed the close of
business on August 4, 2022 (New York time) as the record date for
determining the shareholders entitled to receive notice of the AGM
or any adjournment or postponement thereof. Holders of record of
the Company's Class A ordinary shares or Class B ordinary shares,
each with a par value of US$0.0002 per share, at the close of
business on the record date will be entitled to attend the AGM and
any adjournment or postponement thereof in person.
The notice of the AGM and the Company’s 2021 Annual Report
containing the complete audited financial statements and the report
of auditors for the year ended December 31, 2021, is available on
the Investor Relations Section of the Company’s website at
https://ir.brbiotech.com/.
About Burning Rock
Burning Rock Biotech Limited (NASDAQ: BNR), whose mission is to
guard life via science, focuses on the application of next
generation sequencing (NGS) technology in the field of precision
oncology. Its business consists of i) NGS-based therapy selection
testing for late-stage cancer patients, and ii) cancer early
detection, which has moved beyond proof-of-concept R&D into the
clinical validation stage.
For more information about Burning Rock, please visit:
www.brbiotech.com.
Safe Harbor Statement
This press release contains forward-looking statements. These
statements constitute “forward-looking” statements within the
meaning of Section 21E of the Securities Exchange Act of 1934, as
amended, and as defined in the U.S. Private Securities Litigation
Reform Act of 1995. These forward-looking statements can be
identified by terminology such as “will,” “expects,” “anticipates,”
“future,” “intends,” “plans,” “believes,” “estimates,” “target,”
“confident” and similar statements. Burning Rock may also make
written or oral forward-looking statements in its periodic reports
to the SEC, in its annual report to shareholders, in press releases
and other written materials and in oral statements made by its
officers, directors or employees to third parties. Statements that
are not historical facts, including statements about Burning Rock’s
beliefs and expectations, are forward-looking statements. Such
statements are based upon management’s current expectations and
current market and operating conditions, and relate to events that
involve known or unknown risks, uncertainties and other factors,
all of which are difficult to predict and many of which are beyond
Burning Rock’s control. Forward-looking statements involve risks,
uncertainties and other factors that could cause actual results to
differ materially from those contained in any such statements. All
information provided in this press release is as of the date of
this press release, and Burning Rock does not undertake any
obligation to update any forward-looking statement as a result of
new information, future events or otherwise, except as required
under applicable law.
Contact: IR@brbiotech.com
Burning Rock Biotech (NASDAQ:BNR)
Historical Stock Chart
From Aug 2024 to Sep 2024
Burning Rock Biotech (NASDAQ:BNR)
Historical Stock Chart
From Sep 2023 to Sep 2024